• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Bevacizumab in endometrial cancer treatment.
【24h】

Bevacizumab in endometrial cancer treatment.

机译：贝伐单抗用于子宫内膜癌的治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: There is a critical need to develop effective new strategies for the management of patients with advanced or recurrent endometrial cancer (EC) and molecular targeted therapies; in particular, antiangiogenic drugs represent an interesting field of pharmacological research. One of the most interesting of these agents is bevacizumab, a monoclonal antivascular endothelial growth factor antibody. AREAS COVERED: Mechanism of action and clinical trials of bevacizumab in EC, and suggestions for its future use are reviewed. The most relevant papers and the meeting abstracts published up to December 2011 were used as sources for this review. The purposes of this manuscript are to discuss the rationale of interfering with the process of tumor angiogenesis in EC, to help readers in understanding the mechanism of action of bevacizumab, and to provide a comprehensive summary of initial preclinical and clinical results of this drug in EC patients. EXPERT OPINION: Recent advances in the understanding of the molecular biology of EC have led to development of targeted therapies. Among these, antiangiogenic agents are one of the most promising therapies.
机译：简介：迫切需要开发有效的新策略来治疗晚期或复发性子宫内膜癌（EC）和分子靶向疗法的患者;特别地，抗血管生成药物代表了药理研究的有趣领域。这些药物中最有趣的一种是贝伐单抗，一种单克隆抗血管内皮生长因子抗体。覆盖的领域：综述了贝伐单抗在EC中的作用机理和临床试验，并对其未来使用提出了建议。截止到2011年12月发布的最相关的论文和会议摘要被用作本次审查的资料来源。该手稿的目的是讨论干扰EC中肿瘤血管生成过程的原理，帮助读者理解贝伐单抗的作用机理，并对该药物在EC中的初步临床前和临床结果进行全面总结耐心。专家意见：对EC分子生物学的最新了解已导致靶向治疗的发展。其中，抗血管生成剂是最有前途的疗法之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号